Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791173 | 1.00 | STING1 (0.85) | STING1CYP3A4 | |
| SCHEMBL19451834 | 1.00 | STING1 (0.85) | STING1CYP3A4 | |
| SCHEMBL24467481 | 0.97 | STING1 (0.81) | STING1CYP3A4 | |
| SCHEMBL25073979 | 0.97 | STING1 (0.81) | STING1CYP3A4 | |
| SCHEMBL19451839 | 0.95 | STING1 (0.78) | STING1CYP3A4 | |
| SCHEMBL24467473 | 0.93 | STING1 (0.90) | STING1CYP3A4 | |
| SCHEMBL20886134 | 0.93 | STING1 (0.90) | STING1CYP3A4 | |
| SCHEMBL23327842 | 0.92 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL28614917 | 0.92 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL30206875 | 0.92 | STING1 (1.00) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285755-A1 | Adjuvants | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-29 | — | — | US | claimed |
| EP-4346894-A1 | ADJUVANTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-04-10 | — | — | EP | claimed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-20260083838-A1 | Adjuvant Composition Comprising STING Agonists | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-03-26 | — | — | US | disclosed |
| US-20250255981-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12178851-B2 | Methods for administering STING agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| US-20240285755-A1 | Adjuvants | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-29 | — | — | US | disclosed |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4346894-A1 | ADJUVANTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4277904-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Seagen Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-109608443-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| CN-109071514-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3692033-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | disclosed |
| WO-2019069269-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | STING1 1440/4885CYP3A4 2740/4885 |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-20240285755-A1 | Adjuvants | STING1, TLR3, TLR9 | STING1 1/4885CYP3A4 4646/4885 |
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | STING1 1/4885CYP3A4 4770/4885 |
| US-20260083838-A1 | Adjuvant Composition Comprising STING Agonists | STING1, CGAS, IFNAR1 | STING1 1/4885CYP3A4 4517/4885 |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | AADAC, TAF15, HDAC10 | STING1 748/4885CYP3A4 3022/4885 |
| US-20250255981-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | STING1 1440/4885CYP3A4 2740/4885 |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-12178851-B2 | Methods for administering STING agonists | STING1, CGAS, TLR9 | STING1 1/4885CYP3A4 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.